Navigation Links
Prometheus Launches ProOnc Dx Cancer Diagnostics
Date:10/15/2009

SAN DIEGO, Oct. 15 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the nationwide commercial launch of three new cancer diagnostic products: ProOnc TumorSource Dx, ProOnc Squamous Dx and ProOnc Mesothelioma Dx. Each of these tests is based on recently developed, highly sensitive microRNA technology.

"Prometheus has a long and successful history of providing innovative diagnostics that complement targeted therapeutics to help physicians individualize patient care," said Joseph M. Limber, President and Chief Executive Officer of Prometheus. "Now we are proud to introduce the first three products from our cancer diagnostics portfolio with the launch of ProOnc Dx. We believe that these highly tissue-specific tests provide more objective and quantitative results than current methods, which, may lead to more personalized treatments for patients."

ProOnc TumorSource Dx identifies the tissue-of-origin of a metastatic tumor. The test identifies 25 different tumor types, including colon, liver, brain, breast, kidney, lung, ovary, pancreas, prostate and testis, and measures the expression level of 48 microRNA biomarkers. ProOnc TumorSource Dx uses a proprietary classifier to assign a primary site to the cancer sample based on the microRNA expression in the tumor and may become a critical tool in the detection of cancer of unknown primary (CUP).

ProOnc Squamous Dx classifies non-small cell lung carcinoma tumors into two histological groups: cancers of squamous histology and non-squamous cancers. The test measures the expression level of a squamous microRNA biomarker to differentiate patients that have squamous cell carcinoma of the lung from patients that have non-squamous non-small cell lung cancer.

ProOnc Mesothelioma Dx is a cutting-edge molecular diagnostic test that uses microRNA to differentiate malignant pleural mesothelioma from peripheral adenocarcinoma of the lung and metastatic carcinomas involving the lung and pleura.

"MicroRNAs are small, non-coding sequences of RNA that are critically important in many biological and pathological processes," said Harvey Pass, M.D., Professor of Cardiothoracic Surgery and Director of the Division of Thoracic Surgery and Thoracic Oncology at New York University Langone Medical Center and its NYU Cancer Institute. "The sensitivity and specificity of microRNA-based diagnostics should enable clinicians to differentiate particular cancer tissues with increased confidence, which may ultimately guide medical oncologists to deliver the safest and most efficacious therapy for their patients."

For more information about ProOnc Dx tests, please call (877) 378-4919 or visit www.prometheusoncology.com.

Prometheus acquired exclusive U.S. rights to ProOnc TumorSource Dx, ProOnc Squamous Dx and ProOnc Mesothelioma Dx from Rosetta Genomics (Nasdaq: ROSG) in April 2009. The tests are offered as miRview mets, miRview squamous and miRview meso outside of the U.S. In addition, Prometheus and Rosetta are collaborating to develop two new microRNA-based gastroenterology tests.

About Prometheus

Prometheus Laboratories Inc. is a specialty pharmaceutical and diagnostic company committed to developing and commercializing novel pharmaceutical and diagnostic products to help physicians individualize patient care. Prometheus is a leader in applying the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and is applying these principles to oncology. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary diagnostic testing services. By integrating pharmaceutical products and diagnostic testing services, Prometheus believes it can address the full continuum of care, thereby providing physicians with a comprehensive solution to treat chronic diseases. Prometheus' corporate offices are located in San Diego.

ProOnc TumorSource Dx, ProOnc Squamous Dx and ProOnc Mesothelioma Dx are trademarks of Prometheus Laboratories Inc. miRview mets, miRview squamous and miRview meso are trademarks of Rosetta Genomics Ltd.

SOURCE Prometheus Laboratories Inc.


'/>"/>
SOURCE Prometheus Laboratories Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW
2. Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
3. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
4. Frutarom Launches New Global Branding
5. Cantel Medicals Crosstex Subsidiary Launches New Specially Treated Face Mask Effective Against H1N1 Influenza
6. Iowas Largest Health System Launches First-in-the-Nation Statewide Electronic Prescribing
7. Ethicon Endo-Surgery Launches New Echelon Flex(TM) Endopath(R) Stapler That Delivers Echelon(TM) Compression, Now With Natural Articulation
8. MO BIO Laboratories, Inc. Launches LifeGuard(TM) Soil Preservation Solution
9. AMICAS Launches Major New Version of Radiology Information System at RBMA 2009
10. PARI Respiratory Launches PEP S
11. CVS Caremark Launches Distribution of $3 million in Free Seasonal Flu Shot Vouchers to the Unemployed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... California (PRWEB) , ... June 25, 2016 , ... "With ... fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... customizable and all within Final Cut Pro X . Simply select a ProHand ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
Breaking Medicine News(10 mins):